Hengrui Pharmaceutical (600276.SH): Clinical trials of various drugs such as SHR-9839 (sc) for injection were approved

Zhitongcaijing · 11/21/2025 10:41

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue SHR-9839 (sc) for injections, SHR-A2009 for injections, SHR-1826, HRS-4642 injections, adbelimab injections, Ruikang trituzumab for injections, and -A2102 , the “Drug Clinical Trial Approval Notice” for HRS-7058 capsules and HRS-7058 tablets will conduct clinical trials in the near future. Specifically, a phase IB/II study plan on the safety, tolerability and efficacy of injectable SHR-9839 (sc) combined antineoplastic drugs in solid tumor subjects.